Tyrosine kinase inhibitor
Lazertinib Beats Gefitinib in Treating EGFR-Mutated NSCLC
SG Tylor
In a Phase III study known as LASER301 (NCT04248829) and published in the Journal of Clinical Oncology, lazertinib (formerly YH25448), ...
Rivoceranib Plus Camrelizumab NDA for Unresectable HCC is Accepted by the FDA
SG Tylor
Source – Elevar therapeutics On July 17, 2023, The FDA has accepted a New Drug Application (NDA) for rivoceranib, an ...
Advanced RCC Tumor Sequencing Identifies Host Signatures Associated with Immunotherapy Response
SG Tylor
In a single-center study presented at the 2023 Kidney Cancer Research Summit, researchers found that patients with metastatic renal cell ...
